The Pfizer Rare disease team was very happy to welcome in its Brussels headquarters Christina Verhofstadt and Denis Wolfs from the recently founded AMYBEL patient association. Under the motto “Bring Amyloidosis into the light,” the purpose of Amybel is to inform, guide and support patients with Amyloidosis. The two board members of Amybel shared with us their personal story and how they got diagnosed, which even reinforced our commitment to support them and raise awareness around this rare and often underdiagnosed condition. Amyloidosis causes an abnormal accumulation of parts of proteins and can affect different tissues and organs, such as the heart for instance. An early diagnose can make a real difference in the evolution of the disease. For more information on the disease check today www.amyloidose.be and very soon www.amybel.be as well. #Amyloidosis #RareDisease #RadiOrg #PfizerBelgium Maura Verdoliva Stefaan Osaer Quentin Vander Stricht Dave Ceyssens Marie-Lise Verschelden Arnoud den Ouden Ruben Weckx Michiel Vanmeert, PhD, PharmD Ingrid Van Steenberge Mieke Vandenberghe, MD Bharati Shivalkar Arturo Prieto Rodríguez
What an inspiring initiative! Bringing awareness to rare diseases like Amyloidosis is crucial for early diagnosis and support. Kudos to the Pfizer Rare Disease team and the AMYBEL patient association for their commitment to making a difference.
Are you interested in scorpion venom
Congratulation! Keep it up, you are the best!
Congratulations
Congratulations
Congratualtions
Congrats
APM | Agente Propaganda Médica | APM EXTREME TRAINING | Matriculado GBA y CABA | Concretar estrategias de Productividad | Interpreto datos y cálculo el éxito | Colaborador rentable | Ayudo a posicionarse como líder |
4moIt is clear that Pfizer is committed to improving the lives of patients with amyloidosis, and that collaboration with patient associations is essential to achieve this goal.